Shanghai Shyndec Pharmaceutical (600420.SH) obtained the drug registration certificate for Brexpiprazole Tablets.
Shanghai Shyndec Pharmaceutical (600420.SH) announced that recently, the company received the Drug Registration Certificate for Brexpiprazole Tablets approved and issued by the National Medical Products Administration. Brexpiprazole Tablets are an oral atypical antipsychotic, primarily indicated for the treatment of schizophrenia in adults. The drug modulates neurotransmitters in the brain through multiple mechanisms, including partial agonism of dopamine D2 receptors and 5-HT1A receptors, and antagonism of 5-HT2A receptors, thereby improving psychotic symptoms.
Shanghai Shyndec Pharmaceutical (600420.SH) announced that the company recently received the Drug Registration Certificate for Brexpiprazole Tablets approved and issued by the National Medical Products Administration. Brexpiprazole Tablets are an oral atypical antipsychotic, primarily indicated for the treatment of schizophrenia in adults. The drug modulates neurotransmitters in the brain through multiple mechanisms, including partial agonism of dopamine D2 receptors and 5-HT1A receptors, and antagonism of 5-HT2A receptors, thereby improving psychotic symptoms.
Related Articles
ROKAE ROBOTICS(03752): The 10,000th humanoid force-controlled arm rolls off the production line
HUABAO INTL(00336): Further Subscription of Financial Products
China State Construction Engineering Corporation (601668.SH) recently secured major projects totaling 14.04 billion yuan.
ROKAE ROBOTICS(03752): The 10,000th humanoid force-controlled arm rolls off the production line
HUABAO INTL(00336): Further Subscription of Financial Products
China State Construction Engineering Corporation (601668.SH) recently secured major projects totaling 14.04 billion yuan.
